Is 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide? Is 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide safe for nursing mother and child? Does 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide extracts into breast milk? Does 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide has any long term or short term side effects on infants? Can 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide influence milk supply or can 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide decrease milk supply in lactating mothers?

Used for treatment of Leishmania infection and American Trypanosomiasis (T. cruzi: Chagas Disease, -see specific info) and African (Trypanosomiasis T. gambiensis: Sleeping Sickness). It is excreted into breastmilk in small amounts (Garcia-Bournissen 2010) and there have not been observed problems in infants from treated mothers (Schmid 2012), so many experts consider it compatible with breastfeeding (Sankale 1991 Barennes 2010). 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide has been very well tolerated when administered directly to infants and newborns (Schmid 2012)

Limited information indicates that maternal doses of 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide up to 15 mg/kg daily produce do not cause any adverse serious effects in breastfed infants. Breastmilk levels and a computer simulation found that the dose that an exclusively breastfed infant would receive through breastmilk would be much less than the dose given to treat Chagas disease in newborn infants. Other authors consider that breastfeeding is not contraindicated during the use of 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide.[1][2]

A cohort of 33 infants who were breastfed (extent not stated) by hospitalized mothers taking 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide was followed in the Democratic Republic of the Congo. Thirty mothers took a full course of 30 doses of oral 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide 15 mg/kg daily and all received 14 doses of intravenous eflornithine 400 mg/kg daily for 7 days for human African trypanosomiasis. (sleeping sickness). Nursing mothers also took a median of 4 other concomitant medications. No serious adverse events were reported in any of the breastfed infants.[5]